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Abstract
Background: It has been suggested that the EQ-5D-3 L preference-based measure of health outcome lacks
sensitivity to discriminate between health states in cancer patients. An alternative approach is to use a
disease (cancer) specific preference-based measure, such as the EORTC-8D. A limited number of comparisons
have been made between generic and disease specific preference-based measures. The aim of this study was
to compare the utility scores from the EQ-5D-3 L and the EORTC-8D in a group of patients with oral cancer
or with oral potentially malignant disorders (OPMD).
Methods: Patients (n = 151) with OPMD or oral cancer were recruited consecutively from six hospitals in Sri
Lanka. All participants completed both the EQ-5D-3 L and the EORTC's QLQC-30 instrument. The Sri Lankan
EQ-5D-3 L and EORTC-8D scoring algorithms were employed to estimate utility scores. The utility scores from
the two instruments were compared for discrimination, responsiveness and correlation.
Results: There were significant differences across the two utility scores. The EQ-5D-3 L showed better
discrimination than EORTC-8D with higher effect sizes. There were higher ceiling effects observed in the
EQ-5D-3 L. There was poor correlation between the dimensions of the two instruments except for the
mobility and physical functions.
Conclusion: The two instruments captured different aspects of quality of life. The EQ-5D-3 L demonstrated
better discrimination than the EORTC-8D. In mild conditions EORTC-8D was more responsive and we
recommend further validation of this instrument in diverse cancer conditions.
Background
Economic evaluation is an important aspect of resource
allocation in health care. Cost utility analysis (CUA) is
the most popular method of evaluation in contemporary
health economics [1]. CUA uses Quality Adjusted Life
Years (QALYs) along with costs as the principle outcome
measures. The use of QALYs as an outcome measure
permits evaluation of benefits across different interven-
tions and diseases where QALYs capture changes in both
quantity and quality of life. The QALY plays a major role
in deciding whether a new treatment provides relative
benefits for any additional cost. Thus, this outcome
measure and its sensitivity to discriminate quality of life
changes are crucial in determining value for money.
QALYs use utility scores to quantify the preference for
a given health state [2]. Multi attribute utility instru-
ments (MAUIs), such as the EQ-5D-3 L, have facilitated
health state valuation, with utility scores assigned to all
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health states described by the MAUI based on public
preferences for being in that health state [3, 4]. However,
with the advent of a number of MAUIs [3–7], it is
unclear which instrument performs best in different
disease states [8]. Currently, the National Institute for
Health and Care Excellence (NICE) in the United
Kingdom recommends the EQ-5D-3 L for economic
evaluations [2]. However, it is unclear whether this instru-
ment is capable of discerning utility values in complex
disease conditions that have multiple physical, social,
psychological and economic complications [9]. The recent
development of EQ-5D-5 L is considered to improve the
crude three level structure of the EQ-5D-3 L by hav-
ing 3125 health states. However, national level health
state valuations and comparisons should be conducted
in several countries to ascertain the true nature of
the improvement.
Cancer is a disease condition where debate continues as
to whether disease-specific preference-based measures or
generic measures perform better [9, 10]. It is also a frontier
of research into new treatments aiming to improve both
longevity and quality of life, so it is important that the best
available utility instruments are employed. Recently, a
preference-based measure, the EORTC-8D, was developed
using the 30 items in EORTCs’ QLQC-30 instrument for
use as a disease (cancer) specific preference based measure
[9]. An algorithm developed in a health state valuation
study facilitates estimating EORTC-8D utility values
directly from the QLQC-30 data [9]. Therefore, in clinical
trials and research, one instrument (the QLQ-C30) can be
used to measure changes in quality of life as well as the
utility of cancer health states, reducing the burden of data
collection. For utilities produced with measures like
EORTC-8D, it is important to test whether they are really
more discriminative and responsive than a generic instru-
ment, such as the EQ-5D-3 L, despite their larger number
of potential health states. Whether the utility differ-
ences produced from the disease specific instrument
are significantly different from generic utility scores
between severity groups and over time also needs to
be examined. Furthermore, it is important to ascertain
whether the health spaces covered by the disease
specific instrument are different to the coverage by
generic instruments: Few studies have addressed this
[10, 11]. There is little comparative information between
the EQ-5D-3 L and disease specific instruments and a gap
in the literature about the construct validity of preference
based disease specific instruments.
One of the major cancer conditions experienced in Sri
Lanka is oral cancer. There are current interests to deter-
mine the cost-effectiveness of oral cancer screening and
different treatment methods in Sri Lanka. Therefore, it is
timely to determine which preference-based measure is
most sensitive to the health states associated with this
malignancy, for use in future cost utility analyses.
When considering oral cancer, precursor lesions,
termed Oral Potentially Malignant Disorders (OPMD)
[12], are also important. Major classifications of OPMD,
namely Leukoplakia, Erythroplakia and Oral submu-
cous fibrosis, are associated with a risk of malignant
transformation [13, 14]. The term oral cancer includes
malignancies of the lip, tongue, buccal mucosa, gingiva
and other tissues within the mouth. Cancers of the lip,
oral cavity and oropharynx, taken together, are the most
prevalent cancers among Sri Lankan males with an age
standardized incidence rate of 15.4 per 100, 000 popu-
lation per annum [15]. Oral cancer in Sri Lanka carries
the highest mortality rate among all cancers of 7.1 per
100,000 pa. [16]. Oral cancer has a substantial impact
on quality of life (QoL), particularly through associated
disfigurement, speech, eating and swallowing difficulties,
drooling, financial and social constraints, emotional
disturbances, and issues related to oral rehabilitation and
depression/anxiety due to fear of recurrence. People
presenting with late stage cancer and patients who have
received combined surgery and radiotherapy as treatment
are more likely to have severe reductions in their QoL
compared with those who receive surgery alone for
smaller lesions [17].
The aim of this study is to ascertain if there are signifi-
cant differences between the utility values estimated
from the EQ-5D-3 L and the EORTC-8D for the same
OPMD and oral cancer health states. The study also
sought to determine the discriminative ability of the two
preference measures for OPMD and oral cancer health
states. Findings will have important implications for the
selection of MAUIs to value quality of life in studies and
clinical practice related to the management or oral
health states.
Methods
A cross sectional study design was used. Data were col-
lected from OPMD and oral cancer patients from five
general hospitals from five districts of the country plus a
Dental Teaching Hospital in a sixth district (Kandy) in
Sri Lanka. Inclusion of six districts ensured diversity of
the sample. During the months of June 2013 to February
2014 consecutive individuals diagnosed with an OPMD
or with oral cancer attending the Maxillo-facial clinics
and oral surgery wards were invited to take part. All oral
cancer patients who consented to take part in the study
and attended regular review clinics during this time
period were also recruited. However, OPMD patients
were recruited only at diagnosis: those on review visits
were excluded as most of the review OPMD patients
who had undergone treatment do not have quality of life
problems associated with the disease. Oral cancer
patients just diagnosed (prior to surgery), after surgery,
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during and after adjunctive chemotherapy/radiotherapy
and who came for review visits were included. Ethical
clearance was obtained from Griffith University Human
Research Ethics Committee (MED/29/12/HREC) and
the Sri Lanka Medical Association (ERC/12/022).
Study instruments
Both EQ-5D-3 L and the QLQ-C30 were administered to
participants at the time of the recruitment. The EQ-5D-
3 L is a generic MAUI with five dimensions (mobility, per-
sonal care, usual activities, pain/discomfort and anxiety/
depression) [3]. Each dimension is classified into three
levels (no problem, some problem and severe problems).
Therefore, the EQ-5D-3 L can describe the health space
with 243 health states. The state of full health (11111) is
given the utility value of 1 and that of death, 0. Utility
values can be less than zero for health states regarded as
worse than death. The QLQ-C30 is a 30 item disease-
specific Likert-type questionnaire used widely in cancer
research to collect information on QoL [18]. Of the 30
items, 28 measure responses using a four point Likert
scale. There are two global health questions with a seven
point Likert scale. These 30 items can be scaled to five
functional scales, three symptom scales, a global health
status and six single items to represent QoL [19]. A higher
score for the functional scale or global health status repre-
sents better QoL, while a higher score for a symptom scale
represents lower QoL. However, the scores for these 30
items cannot be used to develop an algorithm to estimate
utilities as the items do not include any preference meas-
ure. The EORTC-8D was developed specifically to provide
scores for various domains of the QLQ-C30. These scores
were derived from preferences of the general population
of the UK (n = 350) who are above 18 years of age to avoid
being in these health states. The EORTC-8D has eight
dimensions (physical functioning, role functioning, pain,
emotional functioning, social functioning, fatigue/ sleep
disturbance, nausea and constipation /diarrhoea) with four
or five levels in each, describing 81,290 health states [9].
Interview
The data were collected by trained house officers and
clinicians attached to the Maxillofacial units. Patients
who provided informed consent were interviewed and
clinical data captured from their hospital records. This
included basic demographic information, co-morbidities
and clinical history of the current OPMD or the oral
cancer condition of the patient. Subsequently, partici-
pants described their current state of health according
to both the five domain descriptive system of the EQ-
5D-3 L questionnaire and the visual analogue scale
(VAS) [20]. Lastly, participants completed the 30-item
QLQC-30 questionnaire [19]. All instruments were
interviewer administered.
Analysis
The oral cancer patients were categorised as treated and
untreated: the former being patients were who had
undergone surgery to remove the tumours (whether or
not there was subsequent chemo- or radio-therapy): the
latter were waiting for surgery.
EORTC QLQ-C30 scaling
Using the recorded QLQC-30 scoring values and the
coding syntax from the EORTC, 30 items of the this
instrument were converted to one global health status,
five functional scales and nine symptom scales [19]. Each
of the QLQC-30 scales range from 0–100. A high score
in functional and global health status represent higher
functioning and better QoL. Higher scores on the
symptom scale represent severe problems.
Utility scores
Using the scored EQ-5D-3 L questionnaires and the Sri
Lankan EQ-5D-3 L utility scoring algorithm, the EQ-5D-
3 L utility scores for each patient’s health state were
generated [19]. The Sri Lankan EORTC-8D algorithm was
used to convert the QLQ C-30 responses to EORTC-8D
utility values [9, 21]. Distributions for the EQ-5D-3 L and
EORTC-8D were plotted using the mean, standard
deviation and the range of the two utility scores.
Psychometric properties of the two measures
Methods of comparing MAUIs are ambiguous. Rowen
et al. compared MAUIs using discrimination, responsive-
ness, agreement and difference across MAUIs in a recent
paper [10]. We followed the same methodology to compare
EQ-5D-3 L and EORTC-8D in this group of oral cancer
and OPMD patients.
Discrimination
A MAUI should be able to distinguish between clinical
severity groups. Utility for one severity group (e.g., oral
cancer stage) should be different from another. When
the severity of the oral cancer increases, utility scores
should decrease, reflecting a worse health state. This also
provides an element of external validity for the MAUI.
The most mild severity group is the OPMD. The more
severe clinical groups are oral cancer stages, defined as,
Stage I - the cancer is less than 2 cm in size, and has not
spread to lymph nodes in the area; Stage 2 - the cancer
is more than 2 cm in size, but less than 4 cm, and has
not spread to lymph nodes in the area; Stage 3 - the
cancer is bigger than 4 cm but has not spread to any
lymph nodes or other parts of the body; Stage 4- the
cancer is bigger than 4 cm without spread or is any size
and has metastasised to regional lymph nodes [22, 23].
Discrimination properties of EQ-5D-3 L and EORTC-
8D were explored using statistical and psychometric
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tests. Kruskal-Wallis test was used to test the signifi-
cance of difference between severity classes for utilities.
The effect size, calculated as the difference in mean
utility between two adjacent severity classes divided by
the mean utility of the milder severity class, was used to
estimate the size of the difference observed between the
mean utilities for severity classes. In each severity class,
the effect sizes were compared between the EQ-5D-3 L
and the EORTC-8D. To compare the effect sizes of the
EQ-5D-3 L and the EORTC-8D, larger effect sizes
denote better disease discriminating ability [24]. The
effect size was categorized into small (0.2-0.5), medium
(0.5-0.8) and large (>0.8), and an effect size of 1 indicates
change in size similar to one standard deviation [25].
Responsiveness
Responsiveness of a MAUI depends on the ability to
capture utility change between time points. As this study
did not have longitudinal data we were unable to analyse
responsiveness. However, another way to categorise
responsiveness of an instrument is to examine its ceiling
and floor effects [26]. The percentage of “full health”
reported for a MAUI determines the ceiling effects.
Floor effects are determined by the percentage of
patients reporting worst health level in each dimensions
[26]. Lower ceiling and floor effects are indicative of good
responsiveness for an instrument. Thus, we also compared
the two MAUIs for their ceiling and floor effects.
Agreement
Due to a potentially skewed distribution of both the EQ-
5D-3 L and the EORTC-8D health states [10], Spearman’s
rho was used to assess the non-parametric correlation
coefficient between the two utility scores and the dimen-
sions between the two instruments [24]. A Spearman’s rho
of >0.5 or < −0.5, was considered a strong correlation [25].
Difference across MAUIs
It is important to determine whether there is significant
difference between EQ-5D-3 L and EORTC-8D utility
values for the same health state experienced by patients.
The differences were calculated and correlations for each
dimension of the two MAUIs examined. Wilcoxon
signed rank test was used to determine significant
difference between the two utility scores (p < 0.05).
Results
Demographics and quality of life
There were 151 OPMD and oral cancer patients who
gave consent to the study. As the questionnaires were
interviewer administered, the majority of patients an-
swered all questions. Three patients who did not provide
the QLQC-30 information were excluded from analysis.
Table 1 summarises the characteristics of the sample.
The majority were males (54.3 %) and above 60 years of
age (52.9 %). There were 57 (37.8 %) OPMD patients,
predominantly oral lichen planus and oral sub mucous
fibrosis; the remainder had oral squamous cell
carcinoma. Of the 94 oral cancer patients, 23.4 %
were awaiting treatment.
EORTC QLQ-C30 scaling
Table 2 shows the mean scores for the QLQC-30 scales
on the quality of life of the patients. The quality of life
of oral cancer patients was substantially lower than for
OPMD patients across all scales. Patients who had
already received treatment for oral cancer had better
quality of life than those awaiting treatment. The func-
tional scale mean values and the global health status
mean values decreased with increasing stage of disease.
The VAS scores were similar to the global health status
scores and were lower than the mean values of the func-
tional scales.
Utility scores
Figure 1 describes the distribution of the utility scores
for both MAUIs. The distribution of both the EQ-
5D-3 L and the EORTC-8D utility values were skewed
to the right. Of the two, the EQ-5D-3 L shows more
skewness and its distribution has more outliers. The
lowest utility from the EQ-5D-3 L was −0.72 com-
pared to −0.15 of the EORTC-8D.
Psychometric properties of the two measures
Discrimination
Frequency Patients were divided into five clinical sever-
ity classes for the four stages of cancer plus OPMD.
Table 3 shows the mean and median utility scores and
effect size for each class. All EORTC-8D mean utility
scores were higher than the EQ-5D-3 L utility scores.
Mean utility values reduced with increasing severity
across both instruments. The EORTC-8D value for
OPMD was the highest (0.9) mean score. For both instru-
ments, utility differences across oral cancer severity classes
were significant (p < 0.05, Kruskal-Wallis test) displaying
good discriminating properties. Table 3 shows effect sizes
for adjacent severity classes. As an example, 0.025 is the
effect size for the mean utility difference observed
between OPMD and cancer stage 1 for the EQ-5D-3 L.
Except in one case, the effect sizes observed are higher for
the EQ-5D-3 L than the EORTC-8D, suggesting better
discrimination for the EQ-5D-3 L instrument.
Responsiveness
Tables 4 and 5 show the distribution of the sample by
the dimensions of the two MAUIs. A large number of
people reported full health (no problems) within the
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EQ-5D-3 L. The related dimensions of mobility (EQ-5D-
3 L) and physical functioning (EORTC-8D) recorded
substantial differences. Percentage of patients who
recorded no problems for mobility (EQ-5D-3 L) and
physical functioning (EORTC-8D) dimensions were
76.2 % and 49 % respectively. The self-care dimension of
the EQ-5D-3 L, which is also related to physical func-
tioning, recorded 86 % of patients reporting they had no
problems compared with 49 % reporting no problems
with physical functioning in the EORTC-8D. How-
ever, both pain/discomfort and anxiety/depression
dimensions of the EQ-5D-3 L had a similar percent-
age of patients reporting no problems compared with
pain and emotional functioning dimensions of the
EORTC-8D.
Few severe levels were reported by patients in both
MAUIs, indicating floor effects. In comparison, the
EORTC-8D had higher floor effects than the EQ-5D-3 L.
This indicates that in severe conditions the EORTC-8D
would be less responsive than the EQ-5D-3 L, but more
responsive in mild conditions.
Agreement
Figure 2 and Table 6 report the correlations between the
two instruments. There is good agreement between the
two utility scores for the better health states, but disagree-
ment for severe health conditions (r = 0.69; P < 0.0001).
Table 6 presents the correlation between EQ-5D-3 L and
EORTC-8D dimensions, with those in bold for related
dimensions. All correlations between related dimensions
are significant (p < 0.05). The highest correlation (0.548)
was observed between the mobility and physical function
dimensions. The other related dimensions reported low
correlations (p > 0.400). The dimensions fatigue, nausea
and constipation/diarrhoea of the EORTC-8D did not
have any related dimension with the EQ-5D-3 L.
Difference across MAUIs
Table 3 shows there are differences between the EQ-5D-
3 L and the EORTC-8D utility scores for the same health
condition experienced by patients. There are significant
Table 1 Demographic characteristics of the sample
Variable N (%)
Gender
Male 82(54.3)
Female 69(45.7)
Age group
18-29 3(2)
30-39 14(9.3)
40-49 22(14.6)
50-59 32(21.2)
60-69 44(29.1)
70 above 36(23.8)
Marital status
Never married 9(6)
Married 135(89.4)
Widow/separated 7(4.6)
Ethnicity
Sinhalese 120(79.5)
Tamil 25(16.6)
Muslim 6(4)
Education
No formal education 16(10.7)
Primary 84(56)
Secondary 44(29.3)
Tertiary 6(4)
Employment
Employed 105(70)
Non-economic activities 38(25.3)
Family worker 7(4.7)
OPMD/ cancer
OPMD 57(37.8)
Oral cancer 94(62.2)
OPMD diagnosis n = 44
Leukoplakia 1(2.3)
Mixed red and white lesions 2(4.5)
Oral sub mucous fibrosis 13(29.5)
Lichen planus 19(43.2)
Other 9(20)
Cancer stage n = 94
Oral cancer Stage I 24(29.6)
Oral cancer Stage II 26(32.1)
Oral cancer Stage III 19(23.5)
Oral cancer Stage IV 12(14.8)
Table 1 Demographic characteristics of the sample (Continued)
Treatment for oral cancer patients n = 94
Treated (post-surgery) n = 72 72(76.6)
Awaiting treatment (pre-surgery) n = 22 22(23.4)
OPMD- Oral potentially malignant disorder; Stage I -The cancer is less than 2 cm
in size, and has not spread to lymph nodes in the area; Stage 2 - The cancer is
more than 2 cm in size, but less than 4 cm, and has not spread to lymph nodes
in the area; Stage 3 - The cancer is bigger than 4 cm but has not spread to any
lymph nodes or other parts of the body; Stage 4- the cancer is either greater
than 4 cm in largest diameter or is of any size but has metastasised to regional
lymph nodes [22, 23]
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differences between instruments for OPMD, oral can-
cer stage 1 and stage 3 (P < 0.05). The low correlation
between related dimensions (Table 6) suggests the
two MAUIs capture different aspects of health in
these patients.
Discussion
This is the first study to examine the difference between
utility values estimated by the EQ-5D-3 L and the
EORTC-8D for health states described by a sample of
OPMD and oral cancer patients. This is also the first
Table 2 Quality of life of the sample according to severity using QLQC-30
Full sample
Mean(SD)
OPMD All Oral
cancer
Oral cancer
Stage I
Oral cancer
Stage II
Oral cancer
Stage III
Oral cancer
Stage IV
Oral cancer
treated
Oral cancer awaiting
treatment
VAS 66(22) 70(22) 63(20) 68(17) 62(19) 57(23) 53(14) 67(22) 57(17)
GHS 61(23) 68(23) 57(23) 64(15) 57(19) 40(17) 48(25) 62(24) 55(17)
Functional scales
PF 80(21) 85(17) 77(23) 87(14) 82(19) 67(20) 61(29) 82(21) 72(23)
RF 73(30) 84(20) 66(32) 76(29) 75(26) 57(30) 46(36) 74(30) 67(31)
EF 78(23) 84(22) 74(23) 81(18) 67(26) 75(22) 59(30) 79(24) 71(20)
CF 81(22) 90(17) 75(22) 83(17) 79(20) 60(24) 67(22) 83(21) 70(22)
SF 80(25) 89(23) 75(26) 85(26) 67(27) 69(23) 61(26) 81(26) 74(24)
Symptom scales
Fatigue 23(20) 16(16) 28(21) 21(19) 29(22) 32(17) 40(21) 22(20) 31(19)
NV 8(20) 5(16) 10(22) 1.3(4.7) 15(29) 12(21) 18(31) 9(21) 7(15)
Pain 27(23) 20(19) 31(24) 20(17) 35(22) 41(22) 43(27) 26(23) 31(21)
Dyspnoea 16(25) 13(25) 17(25) 15(27) 15(25) 16(20) 36(26) 16(26) 15(22)
Insomnia 26(32) 20(28) 30(34) 19(29) 28(30) 38(37) 39(27) 25(33) 31(29)
AL 24(31) 15(23) 30(34) 22(32) 26(36) 44(33) 31(30) 23(32) 30(29)
Constipation 14(26) 8(15) 17(29) 11(27) 18(29) 28(32) 14(30) 14(26) 17(26)
Diarrhoea 11(24) 3(10) 17(28) 11(27) 18(29) 28(32) 14(30) 10(23) 17(26)
FD 32(34) 24(35) 36(33) 25(34) 45(35) 47(32) 47(30) 31(34) 33(34)
Mean (SD)- all given values are mean and standard deviation(SD) for QLQC-30 scores (the QLQC-30 scores are from 0–100, higher the score better the quality of
life); VAS- visual analogue scale; Stage I -The cancer is less than 2 cm in size, and has not spread to lymph nodes in the area; Stage 2 - The cancer is more than
2 cm in size, but less than 4 cm, and has not spread to lymph nodes in the area; Stage 3 - The cancer is bigger than 4 cm but has not spread to any lymph nodes
or other parts of the body; Stage 4 - The cancer is either greater than 4 cm in largest diameter or is of any size but has metastasised to regional lymph nodes;
GHS global health status, PF physical functioning, RF role functioning, EF emotional functioning, CF social functioning, NV nausea and vomiting, AL appetite loss,
FD financial difficulties
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Fig. 1 Distribution of the EQ-5D and the EORTC-8D utility scores. red: EORTC-8D distribution; blue = EQ-5D-3 L distribution
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study to produce a comparison of generic and disease
specific preference based measures from a low/middle
income country [27, 28], and is robust in that it used
country-specific algorithms for both the EQ-5D-3 L and
the EORTC-8D [29].
It is noteworthy that, similar to Rowen et al. [10], our
analysis found the EQ-5D-3 L to have higher discrimin-
ation across cancer severity groups than the EORTC-8D,
the cancer specific preference based measure. A possible
explanation for the finding that the EORTC-8D lacked
discrimination between individuals with different sever-
ities of disease could lie in the algorithm used to convert
QLQC-30 values to EORTC-8D utility scores. This
algorithm was based on a regression model which esti-
mated the utility scores [21]. The preferred model in the
regression analysis did not consider all the levels in the
EORTC-8D as they were sometimes not significant or
inconsistent [21]. Another reason could be the different
time periods which patients are asked to consider in the
two instruments: the EQ-5D-3 L asks respondents to
consider their current health, whereas QLQC-30 asks
them to consider the past week.
Rowen et al. previously compared the EORTC-8D and
the EQ-5D-3 L utility values using a group of patients
with multiple myeloma in the UK [10]. They used the
Karnofsky performance scale to determine the severity
levels of their patients, whereas we used the clinical se-
verity groups described [10]. There is a clear distinction
between the clinical definition of an OPMD, of an overt
oral malignancy, and the four stages of oral cancer: this
enabled us to group our patients without involving extra
scales. We observed that participants with a greater
tumour size reported lower quality of life. As reporting
QoL of the patients was not the main purpose of this
paper, we only used average of functional and symptom
scales from the QLQC-30 data. However, averaging the
functional and symptom scales did not reduce the ability
of the scales to discriminate QoL by the severity levels.
Patients who were waiting for treatment had a lower
QoL, perhaps explained by high anxiety or severe
discomfort. In our analysis, the EORTC-8D values are
very similar to the average of functional scores but
higher than the global health scores.
Our analysis contributes to the discussion of need for
a disease specific preference based measure in cancer
research. We found significant differences between the
EQ-5D-3 L and the EORTC-8D utility values in most of
the severity groups of OPMD and oral cancer. In
addition, we found the EORTC-8D utility values to be
significantly higher than the EQ-5D-3 L utility values for
a given disease state. We also found the EQ-5D-3 L was
more discriminating than the EORTC-8D across the
majority of severity groups. In severe health conditions
the EQ-5D-3 L is more discriminating that the EORTC-
8D due to its larger effect size. This possibly indicates
the ability of EQ-5D-3 L to discriminate severe cancer
health states as well as, or better than, the present
cancer specific method. This poses serious challenges to
the conventional understanding that disease specific
instruments are likely to have greater discrimination.
The significant difference shown in discrimination was
of practical importance as shown by the moderate effect
sizes. Such differences could be pivotal in determining
whether or not a particular health intervention is cost
effective. The lower utility of the EQ-5D-3 L in severe
health states would reflect higher utility gain in a health
Table 3 Discrimination between severity groups of oral cancer
MAUI Cancer severity Mean (SD) Median Effect size
EQ-5D-3 L
OPMD 0.78 (0.19) 0.79
Stage 1 0.76 (0.17) 0.78 0.025
Stage 2 0.69 (0.28) 0.77 0.092
Stage 3 0.57 (0.22) 0.56 0.174
Stage 4 0.48 (0.46) 0.59 0.158
EORTC-8D
OPMD 0.84 (0.17) 0.90
Stage 1 0.83 (0.14) 0.85 0.011
Stage 2 0.73 (0.23) 0.78 0.120
Stage 3 0.65 (0.21) 0.63 0.109
Stage 4 0.61 (0.32) 0.72 0.061
Stage 1 -The cancer is less than 2 cm in size, and has not spread to lymph nodes
in the area; Stage 2 - The cancer is more than 2 cm in size, but less than 4 cm,
and has not spread to lymph nodes in the area; Stage 3 - The cancer is bigger
than 4 cm but has not spread to any lymph nodes or other parts of the body;
Stage 4- The cancer is either greater than 4 cm in largest diameter or is of any
size but has metastasised to regional lymph nodes; SD = standard deviation;
Kruskal-Wallis test was used to determine the significance of difference between
severity classes, p < 0.05; Wilcoxon matched paired rank test was used to test the
significance between utility scores for each severity class, p < 0.05; MAUI =multi
attribute utility instrument
Table 4 Distribution of the EQ-5D-3 L dimensions
Mobility Self-care Usual activities Pain/discomfort Anxiety /depression
No problem 115(76.2) 130(86.1) 107(70.9) 63(41.7) 91(60.3)
Some problem 34(22.5) 19(12.6) 41(27.1) 79(52.3) 56(37.1)
Extreme problem 2(1.3) 2(1.3) 3(2.0) 9(6) 4(2.7)
The numbers indicate the number of patients and percentage in each level of the five dimensions
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intervention where patients gain better health. Thus, it
is quite possible the EQ-5D-3 L would show a higher
outcome gain in QALYs than the EORTC-8D in an
economic analysis.
Although our study did not have longitudinal data, so
that responsiveness over a time period could not be
determined, we have derived information on ceiling and
floor effects of both MAUIs. The EQ-5D-3 L showed
high ceiling effects with large percentages reported in
full health. The influence of ceiling effects was less in
the EORTC-8D. This indicates that EORTC-8D could be
more responsive in mild health conditions than the EQ-
5D-3 L. The higher number of levels in the EORTC-8D,
as well as the fact that respondents rate the QLQC-30
instead of directly rating EORTC-8D, could also in part
account for this.
There is low correlation between the dimensions of the
two MAUIs. This suggests the dimensions of the two
MAUIs capture different aspects of health. The EORTC-
8D was capable of explaining different aspects of quality
of life to EQ-5D-3 L. The dimensions of fatigue, nausea
and constipation/diarrhoea of the EORTC-8D did not
have any related dimensions with the EQ-5D-3 L, reinfor-
cing this concept.
Our results are contrary to the current belief that
disease specific instruments are more sensitive than
generic MAUIs. However, inherent limitations in the
development of the disease specific MAUI considered in
this analysis could be a factor. The EORTC-8D was
developed using QLQC30 data of only one cancer
condition. It was not validated in other types of cancer.
Further research revisiting the psychometric analysis
which produced the original EORTC-8D classification
system is recommended.
Limitations
The cross-sectional nature of our data prevented exam-
ination of responsiveness of the utility values over time.
Table 5 Distribution of the EORTC-8D dimensions
Physical functioning Role functioning Pain Emotional functioning Social functioning Fatigue Nausea Constipation and diarrhoea
Level 1 71(49) 75(50) 69(46) 93(62) 86(57) 106(70) 121(80) 105(70)
Level 2 48(32) 45(30) 58(39) 43(28) 51(34) 36(24) 19(13) 32(21)
Level 3 19(13) 18(12) 18(12) 8(5) 8(5) 6(4) 4(3) 8(5)
Level 4 6(4) 12(8) 5(3) 7(5) 6(4) 3(2) 7(5) 6(4)
Level 5 4(3) - - - - - - -
The numbers indicate number of patients (and percentage) in each level of eight dimensions of the EORTC-8D
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Fig. 2 Correlation between EQ-5D-3 L and EORTC-8D utility scores
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We did not consider the time spent in a given health
state. There is a possibility that remaining in a par-
ticular health state for a long time allows patients to
adapt, and thus deliver higher utility scores. In the
absence of longitudinal data, standardised response
mean, the best method to measure responsiveness
could not be calculated. Instead we used the floor
and ceiling effects which can only indirectly imply
potentially limited responsiveness. Additionally, as the
EQ-5D-3 L was always applied ahead of the QLQC30
there is a potential ordering bias in our data. Ideally,
half of the patients randomly selected should have
received one questionnaire first and the other half the
next questionnaire first.
Conclusion
This is one of a few studies comparing a disease specific
preference-based instrument with a generic instrument.
Moreover, this is the first study to use OPMD and oral
cancer, these being a major public health problem in the
whole of South Asia. The EQ-5D-3 L and the EORTC-
8D utility values were significantly different from each
other. Whilst both preference-based measurements were
able to discriminate between the severity stages of
OPMD and oral cancer, the EQ-5D-3 L utility values
were always lower than the EORTC-8D values for given
cancer health states. Our findings suggest that whilst the
disease specific EORTC-8D may be superior for valuing
mild oral health states, the generic EQ-5D-3 L may be
superior for valuing severe oral health states. Whilst the
ceiling effect of the EQ-5D-3 L is well recognised, the
suggestion that a generic instrument has superior dis-
crimination to a disease specific instrument challenges
conventional wisdom, and should be explored further.
The observed differences could result in quite different
outcomes when determining whether or not a health
intervention was cost effective, and this could have im-
portant implications for policy decisions.
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